MBIO - ムスタング・バイオ （Mustang Bio Inc.） ムスタング・バイオMBIOのチャート
MBIOの企業情報
| symbol | MBIO |
|---|---|
| 会社名 | Mustang Bio Inc （ムスタング・バイオ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Mustang Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is developing its proprietary Chimeric Antigen Receptor (CAR) engineered T cells (CAR -T) technology which uses the patient’s own T cells to engage and destroy specific tumors. The Company through its agreement with City of Hope National Medical Center is using three novel CAR T therapies in the development of cancer treatments including human epidermal growth factor receptor 2 CAR T technology CS1-specific CAR T technology and prostate stem cell antigen CAR T technology. ムスタング・バイオは米国のバイオ医薬品企業。臨床段階で、免疫療法によるがん治療法の開発・商業化に従事する。患者自身の免疫システムの効果を利用し、がん細胞を排除する治療法に焦点を当てる。同社は研究開発のためライセンス供与などでテクノロジ―の所有権を取得し、最終的にはテクノロジ―を市場に投入する方向。本社所在地はニューヨーク。 Mustang Bio, Inc. ("Mustang") is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission ("SEC"). |
| 本社所在地 | 2 Gansevoort Street 9th Floor New York NY 10014 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 781-652-4507 |
| 設立年月日 | 42064 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.mustangbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mbio |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -34.35600 |
| 終値（lastsale） | 5.25 |
| 時価総額（marketcap） | 143132608.5 |
| 時価総額 | 時価総額（百万ドル） 126.22930 |
| 売上高 | 売上高（百万ドル） 0.05000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 79.48530 |
| 当期純利益 | 当期純利益（百万ドル） -33.91500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Mustang Bio Inc revenues increased from $0K to $50K. Net loss increased 30% to $11.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $3.2M to $7.8M (expense) General and administrative increase of 3% to $3.8M (expense). |
MBIOのテクニカル分析
MBIOのニュース
Mustang Bio announces 15-for-1 reverse stock split 2023/04/03 18:05:38 Seeking Alpha
Mustang Bio (MBIO) announced that it will effect a 15-for-1 reverse stock split of its issued and outstanding common stock.The stock is expected to commence trading on split-adjusted…
Mustang Bio Announces Reverse Stock Split 2023/04/03 16:15:00 GlobeNewswire
WORCESTER, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it will effect a 15-for-1 reverse stock split of its issued and outstanding common stock. Mustang expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on April 4, 2023.
Mustang Bio GAAP EPS of -$0.75 beats by $0.01 2023/03/29 20:54:05 Seeking Alpha
Mustang Bio press release (MBIO): FY GAAP EPS of -$0.75 beats by $0.01.As of December 31, 2022, Mustang’s cash and cash equivalents and restricted cash totaled $76.7 million, compared…
Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights 2023/03/29 20:15:00 GlobeNewswire
WORCESTER, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2022.
Mustang Bio Inc. (NASDAQ:MBIO) Stock Ripped 5.04% Year-To-Date, What Will Happen Next? 2023/03/11 15:00:00 Marketing Sentinel
In last trading session, Mustang Bio Inc. (NASDAQ:MBIO) saw 0.55 million shares changing hands with its beta currently measuring 1.92. Company’s recent per share price level of $0.41 trading at -$0.05 or -8.84% at ring of the bell on the day assigns it a market valuation of $41.86M. That closing price of MBIO’s stock is … Mustang Bio Inc. (NASDAQ:MBIO) Stock Ripped 5.04% Year-To-Date, What Will Happen Next? Read More »
Can you now get a good deal on Mustang Bio Inc.’s shares? 2022/12/07 12:54:00 US Post News
Mustang Bio Inc. (NASDAQ:MBIO) marked $0.41 per share on Tuesday, down from a previous closing price of $0.47. While Mustang Bio Inc. has underperformed by -13.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MBIO fell by -78.87%, with highs and lows ranging from $2.18 to […]
Have you been able to find a good deal on Mustang Bio Inc.’s shares? 2022/11/24 15:32:00 US Post News
Mustang Bio Inc. (NASDAQ:MBIO) closed Wednesday at $0.49 per share, down from $0.50 a day earlier. While Mustang Bio Inc. has underperformed by -1.01%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MBIO fell by -77.21%, with highs and lows ranging from $2.20 to $0.40, whereas […]
Mustang Bio Inc. (MBIO) will benefit from these strategies 2022/11/16 15:40:00 US Post News
A share of Mustang Bio Inc. (NASDAQ:MBIO) closed at $0.48 per share on Tuesday, down from $0.49 day before. While Mustang Bio Inc. has underperformed by -2.33%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MBIO fell by -79.28%, with highs and lows ranging from $2.48 […]
Mustang Bio GAAP EPS of -$0.18 beats by $0.02 2022/11/14 23:45:34 Seeking Alpha
Mustang Bio press release (MBIO): Q3 GAAP EPS of -$0.18 beats by $0.02.As of September 30, 2022, Mustang’s cash and cash equivalents and restricted cash totaled $92.4 million,…
Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights 2022/11/14 21:05:00 GlobeNewswire
WORCESTER, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2022.
Mustang Bio (MBIO) Corporate Presentation - Slideshow (NASDAQ:MBIO) 2022/08/17 22:47:25 Seeking Alpha
The following slide deck was published by Mustang Bio, Inc.
Recap: Mustang Bio Q2 Earnings 2022/08/12 04:29:05 Benzinga
Mustang Bio (NASDAQ: MBIO ) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Mustang Bio beat estimated earnings by 9.52%, reporting an EPS of … Full story available on Benzinga.com
Mustang Bio GAAP EPS of -$0.19 beats by $0.02 2022/08/11 21:23:07 Seeking Alpha
Mustang Bio press release (MBIO): Q2 GAAP EPS of -$0.19 beats by $0.02.As of June 30, 2022, Mustang’s cash and cash equivalents and restricted cash totaled $108.4M.
Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights 2022/08/11 20:05:00 GlobeNewswire
WORCESTER, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2022.
That Will Motivate You Today: Akerna Corp. (NASDAQ:KERN -3.76%), Mustang Bio, Inc. (NASDAQ:MBIO 1.60%) 2022/08/08 00:10:25 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post That Will Motivate You Today: Akerna Corp. (NASDAQ:KERN -3.76%), Mustang Bio, Inc. (NASDAQ:MBIO 1.60%) appeared first on Stocks Equity .